ACN_7.4_Full Issue_Digital | Page 32

Written in Blood

Featured research from recent issues of Blood

Risk of Subsequent Malignant Neoplasms Is Low in Children With Hodgkin Lymphoma

A study published in Blood suggests that children and adolescents with intermediate-risk Hodgkin lymphoma have a relatively low cumulative risk of developing subsequent malignant neoplasms ( SMNs ), but radiation therapy appears to increase the risk of SMNs in these patients . The findings were published by Lisa Giulino-Roth , MD , of the Weill Cornell Medical College in New York , and colleagues from the Children ’ s Oncology Group .
In this analysis , researchers studied a group of 1,734 children , adolescents , and young adults who received a new diagnosis of intermediate-risk Hodgkin lymphoma between 2002 and 2009 who participated in the Children ’ s Oncology Group phase III study AHOD0031 . participants were treated with response-based therapy consisting of four cycles of a chemotherapy backbone comprising doxorubicin , bleomycin , vincristine , etoposide , prednisone , and cyclophosphamide ( ABVE-PC ). Treatment was administered with or without field radiation therapy .
Patients who were determined to have a rapid early response after two cycles of ABVE-PC and a complete response following four cycles were randomized to receive 21 Gy involved field radiation therapy ( IFRT ) or no further therapy . In contrast , patients with a slow early response to two cycles of ABVE-PC received a total of four cycles of ABVE-PC , with or without an additional two cycles of dexamethasone , etoposide , cisplatin , event-free survival ( EFS ) and overall survival ( OS ).
At time of diagnosis , the mean age of the overall cohort was 14.5 ± 3.4 years . The estimated 10- year EFS was 81.5 % and the 10-year OS was 96.1 %.
A total of 17 patients developed an SMN during follow-up ( 1 %), while the remaining 1,694 patients had no SMN . Across the entire cohort , the 10-year cumulative incidence of SMN was 1.3 %. SMNs included :
• acute myeloid leukemia ( AML ; n = 3 )
• solid tumors ( n = 11 )
• non-Hodgkin lymphoma ( n = 3 )

There were no differences in baseline clinical or demographic characteristics between patients with or without subsequent malignant neoplasms ( SMN ), but radiation therapy , non-white race , and B symptoms were associated with a higher SMN risk .

There were no differences between patients with versus without SMN at baseline in terms of clinical or demographic characteristics , the authors noted . “ Of note , none of the patients with therapy-related AML in our cohort received DECA , which is relevant as excess risk for leukemia has been reported following treatment with etoposide and cisplatin ,” they added .
As seen in the TABLE , the standardized incidence ratio for any SMN was 9.5 , with a corresponding absolute excess risk of 1.2 per 1,000 person-years .
Researchers reported that the cumulative incidence of SMNs was significantly higher in patients who were treated with radiation therapy ( p = 0.037 ).
Other factors associated with SMN risk in a multivariate analysis included :
This trial evaluated a response-adapted therapeutic approach designed to mitigate long-term toxicities in Hodgkin lymphoma , while ensuring the maintenance of high cure rates . All eligible cytarabine ( DECA ). All patients with a slow early response received IFRT .
The researchers performed an assessment of SMNs at a median follow up of 7.3 years , as well as
• race ( Asian vs . white : hazard ratio [ HR ] = 7.8 ; Black vs . white : HR = 0.8 ; p = 0.028 )
• B symptoms ( HR = 3.1 ; p = 0.027 )
TABLE . Standardized Incidence Ratio and Absolute Excess Risk of Subsequent Malignant Neoplasms
Cancer Diagnosis
Observed Cases
Expected Cases
Standardized Incidence Ratio
95 % CI
Absolute Excess Risk
Any subsequent malignant neoplasm
17
1.79
9.5
4.5-15.2
1.2
Solid tumor within radiotherapy field
10
0.1
105.1
83.2-193.4
0.8
Myelodysplastic syndromes / acute myeloid leukemia
3
0.012
249.9
195.7-730.3
0.2
Non-Hodgkin lymphoma
2
0.02
94.4
63.7-340.9
0.2
Osteosarcoma
1
0.0668
14.7
5.5-81.9
0.1
Embryonal carcinoma
1
0.027
37.4
17.9-207.8
0.1
Papillary thyroid carcinoma
6
0.06
100.1
76.9-217.8
0.5
Mucoepidermoid carcinoma
1
0.008
119.4
68.1-664.5
0.1
Renal cell carcinoma
1
0.005
207.4
124.5-1153.7
0.1
Breast cancer
1
0
Not available
Not available
0.1
• receipt of radiation therapy ( HR = 8.6 ; p = 0.040 )
“ The reasons for these associations , other than treatment with radiation therapy , remain unclear and these associations have not previously been noted ,” the authors concluded , adding that the relatively short follow-up period was a limitation of this study . “ Further follow-up with this cohort and in other cohorts is required to further evaluate these associations .”
Study authors report no relevant conflicts of interest .
Reference Giulino-Roth L , Pei Q , Buxton A , et al . Subsequent malignant neoplasms among children with Hodgkin lymphoma : A report from the Children ’ s Oncology Group . Blood . 2020 December 11 . [ Epub ahead of print ]
30 ASH Clinical News March 2021